Form 4: MPM BioVentures Sells iTeos Therapeutics Shares

MPM BioVentures 2014, L.P. and related entities sold 630,191 shares of iTeos Therapeutics (ITOS) at an average price of $8.06 on May 13, 2025.

Summary

• MPM BioVentures 2014, L.P., along with affiliated entities, disposed of 630,191 shares of iTeos Therapeutics common stock on May 13, 2025.
• The sale was executed at a weighted average price of $8.06 per share, with individual transaction prices ranging from $7.73 to $8.34.
• Following the reported transaction, MPM BioVentures 2014, L.P. and its affiliates continue to hold 2,108,594 shares of iTeos Therapeutics indirectly.
• The reporting entities include MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2018, L.P., MPM BioVentures 2018(B), L.P., and MPM Asset Management Investors BV2018 LLC.
• Luke Evnin and Todd Foley, managing directors of BV 2014 LLC and BV 2018 LLC, are also listed as reporting persons.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the sale of shares by a major shareholder, which could indicate a lack of confidence or a strategic shift. However, the remaining stake is still substantial.

Negatives

• MPM BioVentures, a significant shareholder, has reduced its stake in iTeos Therapeutics, which could be perceived negatively by the market.

Risks

• Continued selling pressure from MPM BioVentures could further depress the stock price of iTeos Therapeutics.
• The reasons behind MPM BioVentures' decision to sell shares are not disclosed, creating uncertainty for investors.

Industry Context

Form 4 filings are standard disclosures for significant shareholders and insiders, providing transparency into their transactions in a company's stock. The sale by MPM BioVentures could be related to portfolio rebalancing or other investment decisions.

Comparison to Industry Standards

• Form 4 filings are a standard part of regulatory compliance for major shareholders in publicly traded companies.
• Sales of this size by venture capital firms are not uncommon, especially after a company has been public for some time and the firm seeks to realize some of its gains.
• It is important to compare this sale to other insider transactions and overall trading volume to assess its significance.

Stakeholder Impact

• Shareholders may react to the news of the sale, potentially impacting the stock price.
• The sale could influence investor sentiment regarding the company's prospects.

Key Dates

Keywords

iTeos Therapeutics, MPM BioVentures, share sale, Form 4, ITOS, stock transaction, beneficial ownership